次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

骨粗しょう症の治療および予防薬の世界市場2014-2024年

Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2014年5月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文217ページになります。
商品コード:VGN236

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
当レポートでは、骨粗しょう症治療・予防薬の世界市場は2014年に83億6000万ドルに達すると推計しており、2024年にかけて堅調な成長を予測しています。同治療薬への需要は増大傾向にあり、医療保険適用の拡大、バイオ医薬品の成功などが売上拡大に寄与していくでしょう。成熟市場国、新興市場国ともに成長が見込まれますが、特にインド、ブラジル、中国、ロシア、韓国では高い成長が期待されます。製品承認の動向、および価格設定が市場に一定の影響をおよぼすと見られます。当レポートでは同市場の2024年に至る市場予測、詳細なセグメント別予測分析に加え、市場動向、研究開発動向、リーディング企業情報などを概略以下の構成でお届けしています。

【レポート構成概要】
・骨粗しょう症治療・予防薬の世界市場予測2014-2024年
・全217ページ、132個のデータ表とグラフ類で分析定量化
・業界専門家オピニオンインタビュー:
- Dr. Karl Grindulis, Consultant Rheumatologist, Sandwell General Hospital, West Bromwich, UK
- Dr. Matthew Drake, Consultant in the Department of Medicine, Division of Endocrinology, Mayo Clinic Rochester, Minnesota, US


・セグメント別市場予測2014-2024年
(吸収抑制薬)VGN236_Osteoporosis Treatment and Prevention World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies Cover.jpgレポート表紙
- ビスホスホネート
- 選択的エストロゲン受容体モジュレーター
- RANKL抗体
- カテプシンK阻害剤
- その他の吸収抑制薬
(アナボリック薬)
- ヒト組換え副甲状腺ホルモン(PTH)
- 抗スクレロスチンモノクローナル抗体
(その他の骨粗鬆症治療)

・主要10製品、製品別売上予測2014-2024年
• Forteo
• Evista
• Prolia
• Actonel/Atelvia
• Fosamax
• Reclast/Aclasta
• Boniva
(※以下、開発途上製品予測)
Our study also provides sales forecasts to 2024 for the following drugs which are currently in development:
• Duavee
• Odanacatib
• Romosozumab

・主要12ヶ国、国別市場予測
• 米国
• 日本
• 中国
• ドイツ
• フランス
• 英国
• イタリア
• スペイン
• インド
• ブラジル
• ロシア
• 韓国
• その他Rest of the World

・リーディング企業8社プロフィール。骨粗鬆治療薬・売上予測2014-2024年、業績、展望、新製品、提携、合弁状況等
• Eli Lilly
• Amgen
• GSK
• Merck
• Pfizer
• Novartis
• Sanofi
• Actavis

・市場動向諸論点
• 世界的な人口高齢化
• 骨粗しょう症への認知度向上と骨の健康教育
• 期待される革新的治療の登場
• 増加傾向にある研究開発予算
• リーディング製品の特許切れ
• ジェネリックとの競合の増大
• 主要国市場における厳格な規制

Visiongain is a trading partner with the US Federal Government
【レポート詳細目次は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies

Table of Contents

1. Executive Summary

1.1 The Global Osteoporosis Drug Market Review
1.2 The Global Osteoporosis Drug Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Osteoporosis

2.1 Osteoporosis Prevalence and Incidence, 2014
2.2 Osteoporosis: The Silent Killer
2.3 Osteoblasts are Critical in Bone Healing
2.4 Classifying Osteoporosis by Types
2.5 Classifying Osteoporosis by Treatments
2.5.1 Antiresorptive Medication
2.5.2 Anabolic Medication
2.6 Osteoporosis Risk Factors

3. The Global Osteoporosis Drug Market, 2014-2024

3.1 Scope of this Report
3.2 The Global Osteoporosis Drug Market in 2013
3.3 The Global Osteoporosis Drug Market: Sales Forecast 2014-2024
3.4 Breakdown of the World Osteoporosis Drug Market by Therapeutic Classes, 2013
3.5 The Global Osteoporosis Drug Market by Therapeutic Classes: Sales Forecast 2014-2024
3.6 Breakdown of the World Osteoporosis Drug Market by Leading Drugs, 2013
3.6.1 The Global Osteoporosis Drug Market by Leading Drugs: Sales Forecast 2014-2024
3.7 Which Osteoporosis Drugs Will Lead the Market in 2024?
3.7.1 Osteoporosis Products Pipeline, 2014
3.7.2 Forteo (Teriparatide) -Eli Lilly, 2014
3.7.3 Evista(Raloxifene) - Eli Lilly, 2014
3.7.4 Prolia (Denosumab) - Amgen, GSK and Daiichi Sankyo, 2014
3.7.5 Actonel/Atelvia (Risendronate) -Sanofi, Actavis, Ajinomoto Pharmaceuticals and Eisai, 2014
3.7.6 Fosamax (Alendronate) - Merck, 2014
3.7.7 Reclast/Aclasta (Zoledronic Acid) - Novartis, 2014
3.7.8 Boniva (Ibandronate) –Roche and GSK, 2014
3.7.9 Duavee (Bazedoxifene/Conjugated Estrogens) – Pfizer and Ligand Pharmaceuticals, 2014
3.7.10 Odanacatib (MK 0822) - Merck, 2014
3.7.11 Romosozumab (AMG 785) – Amgen and UCB, 2014
3.7.12 The Global Osteoporosis Drug Market: Drivers and Restraints 2014-2024

4. Leading National Osteoporosis Drug Markets, 2014-2024

4.1 Regional Breakdown of the World Osteoporosis Drug Market, 2013
4.2 Regional Breakdown of the World Osteoporosis Drug Market: Sales Forecast by Region, 2014-2024
4.3 How Will Regional Market Shares Change to 2024?
4.4 The US Osteoporosis Drug Market, 2013
4.4.1 The US Osteoporosis Drug Market: Forecast 2014-2024
4.5 Reimbursement Situation in the US, 2014
4.5.1 The US Keeps Dominating the Osteoporosis Drug Market: What About Healthcare Coverage?
4.6 The US Osteoporosis Drug Market: Drivers and Restraints, 2014-2024
4.7 The Leading European Osteoporosis Drug Markets, 2013
4.7.1 The Leading European Osteoporosis Drug Markets: Forecasts 2014-2024
4.7.2 The German Osteoporosis Drug Market Forecast, 2014-2024
4.7.3 The French Osteoporosis Drug Market Forecast, 2014-2024
4.7.4 The UK Osteoporosis Drug Market Forecast, 2014-2024
4.7.5 The Italian Osteoporosis Drug Market Forecast, 2014-2024
4.7.6 The Spanish Osteoporosis Drug Market Forecast, 2014-2024
4.8 The Japanese Osteoporosis Drug Market, 2013
4.8.1 The Japanese Osteoporosis Drug Market Forecast, 2014-2024
4.8.2 Recent Trends in the Japanese Osteoporosis Drug Market, 2014
4.9 The BRICK Countries Osteoporosis Drug Market, 2013
4.9.1 The BRICK Countries Osteoporosis Drug Market Forecast, 2014-2024
4.9.2 The Chinese Osteoporosis Drug Market Forecast, 2014-2024
4.9.2.1 Main Companies in the Chinese Osteoporosis Drug Market, 2014
4.9.2.2 Growth Drivers in the Chinese Osteoporosis Drug Market, 2014-2024
4.9.3 The Indian Osteoporosis Drug Market Forecast, 2014-2024
4.9.4 The Russian Osteoporosis Drug Market Forecast, 2014-2024
4.9.5 The Brazilian Osteoporosis Drug Market Forecast, 2014-2024
4.9.6 The South Korean Osteoporosis Drug Market Forecast, 2014-2024
4.9.7 The BRICK Countries Osteoporosis Drug Market: Drivers and Restraints, 2014-2024
4.10 The Osteoporosis Drug Market Forecast in the Rest of the World, 2014-2024
4.10.1 Additional Considerations: Challenges for Aging Populations by Region, 2014

5. Global Antiresorptive Drugs Market, 2014-2024

5.1 The Global Antiresorptive Drugs Market Forecast 2014-2024
5.1.1 Breakdown of the Antiresorptive Drugs Market by Drug Category, 2013
5.2 The Global Antiresorptives Drug Market by Drug Category: Sales Forecast 2014-2024
5.3 The Global Bisphosphonates Market, 2013
5.4 The Global Bisphosphonates Drug Market: Sales Forecast 2014-2024
5.5 Breakdown of the Global Bisphosphonates Market: Sales Forecast by Leading Drugs 2014-2024
5.5.1 Actonel/Atelvia (Risedronate)
5.5.1.1 History of Actonel/Atelvia (Risedronate)
5.5.1.2 Generic Competition for Actonel/Atelvia (Risedronate), 2014
5.5.1.3 Actonel/Atelvia (Risedronate) Sales Forecast 2014-2024
5.5.2 Fosamax (Alendronate)
5.5.2.1 History of Fosamax (Alendronate)
5.5.2.2 Generic Competition for Fosamax (Alendronate), 2014
5.5.2.3 Fosamax (Alendronate) Sales Forecast 2014-2024
5.5.3 Reclast/Aclasta (Zoledronic Acid)
5.5.3.1 Reclast/Aclasta (Zoledronic Acid) Strengths and Weaknesses, 2014
5.5.3.2 Reclast/Aclasta (Zoledronic Acid) in the Leading Regional Markets, 2014
5.5.3.3 Generic Competition for Reclast/Aclasta (Zoledronic Acid), 2014
5.5.3.4 Reclast/Aclasta (Zoledronic Acid) Sales Forecast 2014-2024
5.5.4 Boniva (Ibandronate)
5.5.4.1 Boniva (Ibandronate): Sales Forecast 2014-2024
5.6 The Global SERMs Drug Market: Sales Forecast 2014-2024
5.7 Breakdown of the Global SERMs Market: Sales Forecast by Leading Drugs 2014-2024
5.7.1 Evista (Raloxifene)
5.7.1.1 Generic Competition for Evista (Raloxifene), 2014
5.7.1.2 Evista (Raloxifene) Sales Forecast 2014-2024
5.7.2 Duavee/Aprela (Bazedoxifene and Conjugated Estrogens)
5.7.2.1 Duavee/Aprela (Bazedoxifene and Conjugated Estrogens) in the Leading Regional Markets, 2014
5.7.2.2 History of Duavee/Aprela (Bazedoxifene and Conjugated Estrogens)
5.7.2.3 Duavee/Aprela (Bazedoxifene and Conjugated Estrogens) Sales Forecast 2014-2024
5.8 The Global RANKL Antibody Market: Sales Forecast 2014-2024
5.8.1 Prolia (Denosumab)
5.8.1.1 History of Prolia (Denosumab)
5.8.1.2 Prolia to Drive the Market in 2017
5.8.1.3 Safety Profile
5.8.1.4 Prolia: Patent Expiries
5.8.1.5 Prolia (Denosumab) Sales Forecast 2014-2024
5.9 The Global Cathepsin K Inhibitors Market: Sales Forecast 2014-2024
5.9.1 Odanacatib
5.9.1.1 Odanacatib Sales Forecast 2014-2024
5.10 Other Antiresorptive Drugs, 2014
5.10.1 Protelos
5.10.2 Calcitonin-Salmon
5.10.3 Binosto
5.11 Drivers and Restraints for the Global Antiresorptives Drug Market, 2014-2024

6. The Global Anabolic Drugs Market, 2014-2024

6.1 The Global Anabolic Drugs Market, 2013
6.2 The Global Anabolics Drug Market by Drug Category: Sales Forecast 2014-2024
6.3 The Human Recombinant Parathyroid Hormone Peptides Market, 2014
6.3.1 Forteo (Teriparatide) Market: Sales Forecast 2014-2024
6.3.1.1 Forteo Offers a Differentiating Factor in 2014
6.4 The Anti-Sclerostin Market, 2014
6.4.1 Romosozumab: Sales Forecast 2014-2024
6.5 Other Anabolic Drugs
6.5.1 Blosozumab (LY2541546): Second in Class Sclerostin Antibody
6.5.2 ZP-PTH: Parathyroid by Way Micro Needle Patch
6.5.3 ZT-034: Will Need More Than Biomarkers for Approval
6.5.4 Preotact/Preos: Will it be Introduced in the Market Again?
6.5.5 BA-058 (Abaloparatide): Potential Competitor for Forteo
6.5.6 PTH(1-31)NH2: Future Dual-Action Drug

7. Leading Companies in the Osteoporosis Drug Market, 2014

7.1 Leading Companies in the Osteoporosis Drug Market, 2013
7.2 Expected Company Leaders in the OsteoporosisDrug Market in 2024
7.3 Eli Lilly and Co
7.3.1 Eli Lilly Osteoporosis Drug Sales Forecast, 2014-2024
7.4 Amgen
7.4.1 Amgen’s Osteoporosis Product Portfolio
7.4.2 Amgen Osteoporosis Drug Sales Forecast, 2014-2024
7.5 UCB
7.5.1 UCB Osteoporosis Drug Sales Forecast, 2014-2024
7.6 GSK
7.6.1 GSK Osteoporosis Drug Sales Forecast, 2014-2024
7.7 Merck
7.7.1 Merck Osteoporosis Drug Sales Forecast, 2014-2024
7.8 Actavis
7.9 Sanofi
7.10 Pfizer
7.11 Novartis

8. Qualitative Analysis of the Global Osteoporosis Drug Market, 2014-2024

8.1 Pestel Analysis
8.1.1 Political Factors
8.1.2 Economic Factors
8.1.3 Socio-Cultural Factors
8.1.4 Technological Factors
8.1.5 Environmental Factors
8.1.6 Legal Factors
8.2 Porter’s Five Forces Analysis of the Osteoporosis Drugs Market
8.2.1 Competitive Rivalry: High Rivalry Among Competitors
8.2.1.1 Eli Lilly and Amgen Dominate the Biological Osteoporosis Drug Market
8.2.2 Potential Entrants into the Osteoporosis Drug Market: Low Threat of New Entrants
8.2.3 Medium Threat of Substitutes: Who Are The Latent Substitutes?
8.2.4 High Power of Suppliers: Drug Manufacturers Still Have the Power to Lead the Market
8.2.5 High Power of Buyers: Big Pharma to Engulf Smaller Companies
8.3 SWOT Analysis and Strategies
8.3.1 Strengths: Smart Thinking
8.3.2 Weaknesses: Not An Easy Market
8.3.2.1 Patent Expiries
8.3.3 Opportunities: Changing Social Trends
8.3.4 Threats: Highly Stringent but Necessary Regulations
8.3.4.1 Drug Side-Effect Publicity
8.3.4.2 Reimbursement for Bone Metabolism Drugs
8.4 Challenges to Overcome for the Future Osteoporosis Drug Market

9. Expert Opinions

9.1 Interview with Dr. Karl Grindulis, Consultant Rheumatologist at Sandwell General Hospital, West Bromwich, UK
9.1.1 Calcitonin-Salmon in the UK
9.1.2 Personalised Medicine
9.1.3 Expert Views on Romosozumab
9.1.4 Key Factors for the Future
9.2 Interview with Dr. Matthew Drake, Consultant in the Department of Medicine, Division of Endocrinology, Mayo Clinic Rochester, Minnesota, US
9.2.1 Skeletal Anabolic Agents Remain the Biggest Unmet Need
9.2.2 Calcitonin-Salmon: not Recommendable
9.2.3 Shifting to Generics
9.2.4 Romosozumab: Potential Blockbuster
9.2.5 Odanacatib: Intriguing Future Performance
9.2.6 Focusing on Patients with Rare Skeletal Disorders may Give Some Answers

10. Conclusions

10.1 The World Osteoporosis Drug Market by Therapeutic Classes, 2013
10.2 The World Osteoporosis Drug Market Forecast by Drug Category, 2014-2024
10.3 The Global Osteoporosis Drug Market Forecast by Regional Markets, 2014-2024
10.4 The Global Osteoporosis Drug Market Forecast by Leading Drugs, 2014-2024
10.4.1 Leading Companies for the Osteoporosis Drug Market
10.5 Drivers for the Osteoporosis Drugs Market, 2014-2024

List of Tables

Table 1.1 The Global Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Country, 2013-2024
Table 2.1 Mechanisms Involved in Bone Grafting
Table 3.1 Treatments for Osteoporosis, by Therapeutic Classes, Drug Category and Branded Drugs, 2014
Table 3.2 The Global Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 3.3 The Global Osteoporosis Drug Market: Revenue ($bn) and Market Shares (%) by Therapeutic Classes, 2013
Table 3.4 The Global Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Classes, 2013-2024
Table 3.5 The Global Osteoporosis Drug Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2013
Table 3.6 Patent Expiry Dates for the Leading Osteoporosis Drugs in US and EU
Table 3.7 The Global Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drugs, 2013-2024
Table 3.8 The Global Osteoporosis Drug Market: Market Shares (%) by Leading Drugs, 2013, 2018 and 2024
Table 3.9 Osteoporosis Drugs in Development, 2014
Table 4.1 The Global Osteoporosis Drug Market: Revenue ($bn) and Market Shares (%) by Regional Markets, 2013
Table 4.2 The Global Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Regional Market, 2013-2024
Table 4.3 The Global Osteoporosis Drug Market: Market Shares (%) by Leading Regional Markets, 2013, 2018 and 2024
Table 4.4 The US Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.5 The EU5 Osteoporosis Drug Market: Revenue ($bn) and Global / Regional Market Shares (%) by Country, 2013
Table 4.6 Median Age in EU5 from 1960 to 2060, by Country
Table 4.7 EU5 Osteoporosis Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Country, 2013-2024
Table 4.8 The German Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.9 The French Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.10 The UK Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.11 The Italian Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.12 The Spanish Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.13 The Japanese Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.14 The BRICK Osteoporosis Drug Market: Revenue ($bn) and Global / Regional Market Shares (%) by Country, 2013
Table 4.15 The BRICK Osteoporosis Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Country, 2013-2024
Table 4.16 The Chinese Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.17 The Indian Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.18 The Russian Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.19 The Brazilian Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.20 The South Korean Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.21 The ROW Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 5.1 The Global Antiresorptive Drugs Market: Revenue ($bn) and Market Shares (%) by Drug Category, 2013
Table 5.2 The Global Antiresorptives Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Drug Category, 2013-2024
Table 5.3 The Global Bisphosphonates Drug Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2013
Table 5.4 The Global Bisphosphonates Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%),2013-2024
Table 5.5 The Global Bisphosphonates Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drugs, 2013-2024
Table 5.6 Actonel / Atelvia: Sales ($bn) and Market Shares (%) by Company, 2013
Table 5.7 Actonel / Atelvia Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%),2013-2024
Table 5.8 Fosamax Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%),2013-2024
Table 5.9 Reclast/Aclasta Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%),2013-2024
Table 5.10 Boniva Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%),2013-2024
Table 5.11 The Global SERMs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%),2013-2024
Table 5.12 The Global SERMs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drugs, 2013-2024
Table 5.13 Evista Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 5.14 Duavee Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 5.15 Prolia: Sales ($bn) and Market Shares (%) by Company, 2013
Table 5.16 Prolia Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 5.17 Odanacatib Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 6.1 The Global Anabolic Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Drug Category, 2013-2024
Table 6.2 Hormones Involved in Bone Metabolism
Table 6.3 Forteo Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 6.4 Romosozumab Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 7.1 Leading Companies for the Global Osteoporosis Drug Market: Revenue ($bn), Drug Market Shares (%) and Company Market Shares (%) by Leading Drugs, 2013
Table 7.2 Forecasts for the Leading Companies in the Global Osteoporosis Drug Market: Revenue ($bn), Drug Market Shares (%) and Company Market Shares (%) by Leading Drugs, 2024
Table 7.3 Eli Lilly Osteoporosis Drug Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drugs, 2013-2024
Table 7.4 Prolia Patents Expiration Dates
Table 7.5 Amgen Osteoporosis Drug Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drugs, 2013-2024
Table 7.6 UCB Osteoporosis Drug Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drug, 2013-2024
Table 7.7 GSK Osteoporosis Drug Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drugs, 2013-2024
Table 7.8 Merck Osteoporosis Drug Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%)by Leading Drugs, 2013-2024
Table 7.9 Actavis Osteoporosis Drug Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drug, 2013-2024
Table 7.10 Sanofi Osteoporosis Drug Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drug, 2013-2024
Table 10.1 Segmentation of the Osteoporosis Drug Market, 2014

List of Figures

Figure 1.2 Global Osteoporosis Drug Market Segmentation
Figure 3.1 The Global Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 3.2 The Global Osteoporosis Drug Market: Revenue ($bn) by Therapeutic Classes, 2013
Figure 3.3 The Global Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%) by Therapeutic Classes, 2013-2024
Figure 3.4 The Global Osteoporosis Drug Market: Revenue ($bn) by Leading Drugs, 2013
Figure 3.5 The Global Osteoporosis Drug Market Forecast: Revenue ($bn) by Leading Drugs, 2013-2024
Figure 3.6 The Global Osteoporosis Drug Market: Market Shares (%) by Leading Drugs, 2013
Figure 3.7 The Global Osteoporosis Drug Market: Market Shares (%) by Leading Drugs, 2018
Figure 3.8 The Global Osteoporosis Drug Market: Market Shares (%) by Leading Drugs, 2024
Figure 3.9 Historic and Projected Timeline for the Osteoporosis Drug Market, 2014
Figure 3.10 The Global Osteoporosis Drug Market: Drivers and Restraints, 2014-2024
Figure 4.1 The Global Osteoporosis Drug Market: Revenue ($bn) by Regional Markets, 2013
Figure 4.2 The Global Osteoporosis Drug Market Forecast: Revenue ($bn) by Regional Markets, 2013-2024
Figure 4.3 The Global Osteoporosis Drug Market: Market Shares (%) by Leading Regional Markets, 2013
Figure 4.4 Global Osteoporosis Drug Market: Market Shares (%) by Leading Regional Markets, 2018
Figure 4.5 Global Osteoporosis Drug Market: Market Shares (%) by Leading Regional Markets, 2024
Figure 4.6 The US Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.7 The US Osteoporosis Drug Market: Drivers and Restraints, 2014-2024
Figure 4.8 The EU5 Osteoporosis Drug Market: Global Revenues ($bn) by Country, 2013
Figure 4.9 EU5 Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%) by Country, 2013-2024
Figure 4.10 The German Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.11The French Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.12 The UK Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.13 The Italian Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.14 The Spanish Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.15 The Japanese Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.16 The BRICK Osteoporosis Drug Market: Global Revenues ($bn) by Country, 2013
Figure 4.17 The BRICK Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%) by Country, 2013-2024
Figure 4.18 The Chinese Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.19 The Indian Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.20 The Russian Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.21 The Brazilian Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.22 The South Korean Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.23 The BRICK Countries Osteoporosis Drug Market: Drivers and Restraints, 2014-2024
Figure 4.24 The ROW Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.1 The Global Antiresorptive Drugs Market Within the Osteoporosis Drug Market: Market Shares (%) by Therapeutic Classes and by Drug Category, 2013
Figure 5.2 The Global Antiresorptives Drug Market Forecast: Revenue ($bn) and AGR (%) by Drug Category, 2013-2024
Figure 5.3 The Global Bisphosphonates Market: Market Share (%) by Leading Drugs, 2013
Figure 5.4 The Global Bisphosphonates Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.5 The Global Bisphosphonates Drug Market Forecast: Revenue ($bn) by Leading Drugs, 2013-2024
Figure 5.6 Actonel / Atelvia Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.7 Fosamax Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.8 Reclast/Aclasta Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.9 Boniva Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.10 The Global SERMs Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.11 The Global SERMs Market Forecast: Revenue ($bn) by Leading Drugs, 2013-2024
Figure 5.12 Evista Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.13 Duavee Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.14 Prolia Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.15 Odanacatib Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.16 The Global Antiresorptive Drug Market: Drivers and Restraints, 2014-2024
Figure 6.1 The Global Anabolic Drug Market Forecast: Revenue ($bn) and AGR (%) by Drug Category, 2013-2024
Figure 6.2 Forteo Revenue Forecast: Revenue ($bn) and AGR (%),2013-2024
Figure 6.3 Romosozumab Revenue Forecast: Revenue ($bn) and AGR (%),2013-2024
Figure 7.1 Market Shares (%) of the Leading Companies for the Global Osteoporosis Drug Market, 2013
Figure 7.2 Market Shares (%) of the Leading Companies for the Global Osteoporosis Drug Market, 2024
Figure 7.3 Eli Lilly Osteoporosis Drug Sales Forecast: Revenue ($bn) and AGR (%) by Leading Drugs, 2013-2024
Figure 7.4 Amgen Osteoporosis Drug Sales Forecast: Revenue ($bn) and AGR (%) by Leading Drugs, 2013-2024
Figure 7.5 UCB Osteoporosis Drug Sales Forecast: Revenue ($bn) and AGR (%) by Leading Drugs, 2013-2024
Figure 7.6 GSK Osteoporosis Drug Sales Forecast: Revenue ($bn) and AGR (%) by Leading Drugs, 2013-2024
Figure 7.7 Merck Osteoporosis Drug Sales Forecast: Revenue ($bn) and AGR (%) by Leading Drugs, 2013-2024
Figure 7.8 Actavis Osteoporosis Drug Sales Forecast: Revenue ($bn) and AGR (%) by Leading Drug, 2013-2024
Figure 7.9 Sanofi Osteoporosis Drug Sales Forecast: Revenue ($bn) and AGR (%) by Leading Drug, 2013-2024
Figure 8.1 Porter’s Five Forces Analysis of the Osteoporosis Drug Market, 2014-2024
Figure 10.1 The Global Osteoporosis Drug Market Shares (%) by Therapeutic Class, 2013
Figure 10.2 The Global Osteoporosis Drug Market Forecast: Revenue ($bn) by Drug Categories, 2013-2024
Figure 10.3 The Global Osteoporosis Drug Market Forecast: Revenue ($bn) by Regional Market, 2013-2024
Figure 10.4 The Global Osteoporosis Drug Market Forecast: Revenue ($bn) by Leading Drugs, 2013-2024

掲載企業リスト

Companies Listed

AbiogenPharma S.p.A
Ablynx
Actavis
Ahn-Gook Pharmaceutical
Ajinomoto Pharmaceuticals Co
Almirall
Amgen
Anda, Inc
Apotex Inc
Asahi Kasei
Astellas
AstraZeneca
Aurobindo Pharma
Aventis
Aventis Pharma Ltd
Azelon Pharmaceuticals
Banner Pharmacaps
Banyu
Barr Pharmaceuticals
Bayer
Celltech
Chugai Pharmaceutical Co. Ltd
Ciba Specialty Chemicals
Ciba-Geigy
Daiichi Sankyo
Dow Jones Industrial Average
EffRx Pharmaceuticals
Eisai Co., Ltd
Eli Lilly and Company
Eli Lilly Japan K.K
Fermenta Biotech
Glaxo Wellcome plc
GlaxoSmithKline (GSK)
Hoffmann-La Roche (Roche)
Jiangsu Hengrui Medicine Co., Ltd
LaboratoriosAtral
Lacer S.A
Ligand Pharmaceuticals
Medis
Merck & Co
Merck Frosst
Merck Sharp & Dohme
Nordic Bioscience
Novartis
Novartis International AG
NPS Pharmaceuticals
Nycomed
Ono Pharma
OsteoGeneX
Pfizer, Inc
Procter & Gamble (P&G)
Qingdao Chia Tai Haier Pharmaceutical Co., Ltd
QS Pharma
Radius Health Inc.
Roche
Sandoz
Sanofi Pasteur
Sanofi S.A
Sanofi-Aventis
Sanofi-Synthélabo
Searle
Servier
SmithKline Beecham plc
Sumitomo Pharma
Taisho
Taisho Pharmaceutical Holdings
Takeda
Takeda Pharmaceutical Co., Ltd
Tarsa
Teva Pharmaceutical Industries
UCB
Unigene Laboratories
Warner Chilcott
Wyeth Pharmaceuticals
Zosano Pharma

Other Organisations Mentioned in this Report

American Society for Bone and Mineral Research (ASBMR)
British National Formulary (BNF)
Derwent World Patent Index
Duke University Medical Centre
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
German Federal Joint Committee
Harvard College
Health Canada
International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
International Osteoporosis Foundation (IOF)
Japanese Ministry of Health, Labour, and Welfare
Mayo Clinic
Ministry of Civil Affairs of China
National Health Service (NHS)
National Institute for Health and Care Excellence (NICE)
National Osteoporosis Foundation (NOF)
Pedriatic Investigation Plan (PIP)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Plaintiffs’ Steering Committee
Sandwell General Hospital
The Committee for Medicinal Products for Human Use (CHMP)
The Committee to Evaluate Drugs (CED)
The United Nations
US Preventive Services Task Force
Washington University
World Bank
World Health Organization (WHO)


プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。